0001209191-23-013848.txt : 20230228
0001209191-23-013848.hdr.sgml : 20230228
20230228181925
ACCESSION NUMBER: 0001209191-23-013848
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230224
FILED AS OF DATE: 20230228
DATE AS OF CHANGE: 20230228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Albertson Tina M.
CENTRAL INDEX KEY: 0001917391
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 23688313
MAIL ADDRESS:
STREET 1: C/O LYELL IMMUNOPHARMA, INC.
STREET 2: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-24
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001917391
Albertson Tina M.
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
4049
D
Option (right to buy)
2.13
2023-02-24
4
A
0
700000
0.00
A
2033-02-23
Common Stock
700000
700000
D
Includes 2,495 shares acquired on May 18, 2022 and 1,554 shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following
forty-two months.
/s/ Hector Casab, as Attorney-in-Fact
2023-02-28